+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Superconducting, Permanent Magnet), By Application (Clinic / Clinical Imaging, Experiment / Research), By Field Strength (1.5T, 3T, Below 1.5T, 7T and Above), By End User (Hospitals, Diagnostic Imaging Centers, Academic & Research Institutions, Other Healthcare Settings), and Regional Forecast, 2026-2034
The global MRI (Magnetic Resonance Imaging System) market was valued at USD 5.84 billion in 2025 and is estimated at USD 6.06 billion in 2026. The market is projected to reach USD 8.10 billion by 2034, exhibiting a 3.7% CAGR during 2026–2034.
Magnetic resonance imaging systems use static magnetic fields, gradient fields and radiofrequency energy to generate detailed cross-sectional images and, in some systems, spectroscopy information without ionizing radiation. MRI is particularly valuable in neurology, musculoskeletal imaging, oncology, cardiovascular imaging, abdominal imaging and research because of its high soft-tissue contrast and ability to acquire multiple tissue-weighted and functional sequences.
The market is increasingly defined by productivity rather than field strength alone. Major manufacturers are integrating deep-learning reconstruction, automated planning, faster sequences, wide-bore design and simplified siting. New 1.5T platforms from Siemens, GE HealthCare and Philips emphasize dramatically lower helium requirements, while 3T and 7T systems continue to expand premium neuro, cardiac, oncology and research applications.
Regulatory activity remained high through 2025–2026. FDA cleared multiple Siemens MAGNETOM Flow configurations, including Flow.Ace and Flow.Plus in February 2026 and Flow.Elite, Flow.Neo, Flow.Rise and Flow.Pure in July 2026. GE HealthCare received FDA clearances in February 2026 for SIGNA Sprint with Freelium, SIGNA Bolt and SIGNA One, reinforcing a competitive cycle centered on AI-enabled workflows, sealed magnets and more flexible installation.
The study covers complete MRI systems used for clinical diagnostic imaging and research, including permanent-magnet and superconducting architectures across multiple field strengths.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Permanent Magnet; Superconducting |
| By Application | Clinic / Clinical Imaging; Experiment / Research |
| By Field Strength | Low-field / High-V; 1.5T; 3T; 7T and Above |
| By Architecture | Closed Bore; Wide Bore; Open / Low-field; Dedicated / Specialized |
| By End User | Hospitals; Diagnostic Imaging Centers; Academic & Research Institutions; Other Healthcare Facilities |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | GE HealthCare; Siemens Healthineers; Philips; Canon Medical Systems; United Imaging Healthcare; Fujifilm Healthcare / Hitachi; Neusoft Medical Systems; Anke High-Tech; Alltech Medical Systems; Wandong Medical |
MRI remains essential in neurological disease, musculoskeletal injury, oncology and cardiovascular assessment. Its soft-tissue contrast and non-ionizing nature make it suitable for repeated and complex imaging, sustaining replacement and expansion demand across tertiary care.
Deep-learning reconstruction and automated scan planning reduce noise, shorten acquisitions and standardize protocol execution. Productivity improvement is increasingly important because hospitals need more examinations per installed system without compromising image quality.
Traditional superconducting MRI systems historically required large helium inventories and quench infrastructure. Siemens Flow, Philips BlueSeal and GE Freelium systems reduce or eliminate helium-refill dependence, lowering siting complexity and sustainability risk.
MRI requires major upfront investment, specialized installation, shielding, power, cooling and trained personnel. Small hospitals and lower-resource markets often prefer mid-field, compact or refurbished systems when advanced 3T capabilities do not justify total ownership cost.
North America, Japan and Western Europe already have substantial installed bases. Growth therefore comes from replacement with faster AI-enabled systems, helium-efficient magnets, wide bores and higher-performance gradients as much as from net-new scanner installations.
Siemens Flow uses 0.7 litres of helium in a sealed circuit, Philips BlueSeal uses about 7 litres in a sealed system, and GE's Freelium platform targets helium-independent operation. Reduced cryogen dependence can lower installation risk and expand siting flexibility.
Systems such as Siemens MAGNETOM Free.Max use 0.55T field strength combined with deep-learning reconstruction and an 80 cm bore. Lower field can reduce siting and implant-related constraints while digital reconstruction recovers image quality.
GE's SIGNA Bolt and other high-performance 3T systems target advanced neurological, cardiac, oncology and research applications where signal-to-noise ratio and gradient performance justify higher investment.
The 2026 deployment of a hybrid relocatable MAGNETOM Flow.Elite in the UK demonstrates how helium-independent designs can support temporary, modular and network-based capacity expansion.
GE HealthCare launched the Made-in-India SIGNA Prime Elite in early 2026, while United Imaging and other Asian manufacturers are expanding domestic production. Local manufacturing can reduce cost, shorten service response and support government procurement.
MRI system value is determined by magnet architecture, field strength, gradients, RF coils, reconstruction software, workflow automation and siting requirements.
| Technology Tier | Typical Positioning | Market Relevance |
|---|---|---|
| Permanent / low-field MRI | Lower field, often open or compact architectures with reduced infrastructure requirements. | Supports accessibility, musculoskeletal, interventional and selected routine imaging niches. |
| 1.5T superconducting MRI | Mainstream general-purpose clinical MRI across neurology, MSK, body, cardiac and oncology imaging. | Largest installed commercial tier because it balances diagnostic capability, throughput and cost. |
| 3T MRI | Higher signal and advanced gradient performance for neuro, MSK, prostate, cardiac and research imaging. | Premium growth tier in tertiary hospitals and advanced diagnostic centers. |
| 7T and ultra-high field | Highest research/advanced neuro performance with more specialized workflow and siting. | Small revenue volume but high strategic value and research differentiation. |
| AI reconstruction & workflow | Deep learning for denoising, acceleration, planning and automation across field strengths. | Increasingly important for productivity, consistency and patient throughput. |
The market is segmented into Permanent Magnet and Superconducting systems. Superconducting systems represent the dominant commercial segment and account for roughly four-fifths of the core system market.
Superconducting magnets support mainstream 1.5T, 3T and 7T systems with high field homogeneity and strong signal performance. They dominate hospital and diagnostic-center installations and attract most advanced workflow innovation.
Permanent-magnet and related low-field systems have lower cryogenic requirements and can support open or dedicated imaging. Their role is strongest where siting simplicity, access, lower cost or specific musculoskeletal applications are prioritized.
Clinical imaging is the dominant application, while experimental and academic research drives demand for advanced gradients, spectroscopy, functional MRI and ultra-high-field capability.
Routine clinical MRI spans brain, spine, joints, abdomen, pelvis, breast, cardiac and oncology applications. High patient volumes make workflow efficiency and standardized protocols central purchasing criteria.
Academic institutions and research hospitals use MRI for fMRI, diffusion, spectroscopy, quantitative imaging, biomarker development and advanced sequence research. These sites disproportionately adopt 3T and 7T platforms.
The commercial center of gravity remains 1.5T, while 3T expands in advanced clinical care and lower-field systems are re-emerging through improved digital reconstruction.
1.5T systems provide broad diagnostic capability and remain the most versatile choice for high-volume clinical imaging. New sealed-magnet platforms are reducing infrastructure burden.
3T systems provide higher signal-to-noise ratio and are preferred for advanced neuro, MSK, prostate, cardiac and research protocols where image detail and speed justify higher cost.
0.55T and other low-field systems are gaining renewed attention because of easier siting, wider bores, lower fringe fields and the ability to use AI reconstruction to improve image quality.
7T remains concentrated in advanced neuroscience and research. Clinical applications are expanding selectively, but infrastructure, cost and protocol complexity limit wider adoption.
Hospitals lead MRI spending because they require broad multi-specialty imaging, emergency access and advanced applications. Diagnostic centers are the most commercially productivity-focused buyers.
Hospitals purchase multi-purpose MRI systems for neurology, orthopedics, oncology, cardiovascular and inpatient imaging. Large academic hospitals often operate multiple 1.5T and 3T systems plus research platforms.
Independent and networked imaging centers emphasize throughput, appointment efficiency, patient comfort and low operating cost. AI reconstruction and wide-bore design can materially affect center economics.
Research institutions prioritize high gradients, advanced coils, spectroscopy, functional imaging and open software environments rather than only routine throughput.
Specialty orthopedic centers, mobile/relocatable services and regional clinics create additional demand for lower-field, compact or flexible siting models.
North America is the largest regional market. The United States has one of the world's highest MRI unit densities, substantial hospital capital spending, advanced reimbursement and strong academic imaging research. The region is also an early adopter of AI reconstruction, 3T/7T systems and new FDA-cleared sealed-magnet platforms.
Europe is a major mature market with strong MRI engineering and manufacturing capabilities. Germany, France and the United Kingdom maintain large installed bases, while procurement increasingly emphasizes lower helium consumption, energy efficiency and total lifecycle cost.
Asia-Pacific is the fastest-growing large region. China and India are expanding hospital and diagnostic-center capacity, Japan and South Korea maintain advanced high-field imaging, and regional manufacturers such as United Imaging and Neusoft are increasing competition.
Brazil, Mexico and Argentina account for most regional demand. Public-private imaging expansion supports new installations, but currency and capital constraints make refurbished and cost-efficient 1.5T systems important.
Gulf states are investing in advanced tertiary-care MRI, while broader African access remains limited by capital and specialist shortages. Compact, lower-helium and flexible-siting systems can improve feasibility in developing networks.
MRI systems are regulated as Class II magnetic resonance diagnostic devices in the United States and must satisfy imaging-performance, electromagnetic and patient-safety requirements.
| Requirement / Evidence | Current Context | Market Effect |
|---|---|---|
| FDA 21 CFR 892.1000 | Nuclear magnetic resonance imaging systems are Class II devices under product code LNH. | Requires 510(k) clearance and recognized technical performance testing. |
| NEMA image-quality standards | FDA recognizes standards covering SNR, image uniformity and coil performance. | Supports standardized system validation and quality control. |
| 2026 FDA clearances | Multiple Siemens MAGNETOM Flow variants and GE SIGNA systems received FDA clearance during 2026. | Shows rapid ongoing platform iteration and competition. |
| Helium / siting infrastructure | Sealed magnet designs reduce helium inventory and can remove or simplify quench-pipe requirements. | Lowers facility construction barriers and improves lifecycle sustainability. |
The market is concentrated around three global leaders but is becoming more competitive as Chinese manufacturers expand and major vendors refresh their magnet and AI platforms.
Siemens spans low-field High-V, mainstream 1.5T Flow, 3T and 7T MRI. The Flow platform's 0.7-litre helium design and 2026 FDA clearances strengthen its sustainability and workflow positioning.
GE's 2026 FDA-cleared SIGNA Sprint with Freelium, SIGNA Bolt and SIGNA One refresh 1.5T, 3T and AI workflow layers. Its Made-in-India SIGNA Prime Elite also supports emerging-market expansion.
Philips differentiates through BlueSeal helium-free operations, SmartSpeed AI acceleration and a full 1.5T/3T portfolio. Its sealed magnet contains about 7 litres of helium.
These companies compete through broad clinical portfolios, regional strength and increasingly advanced 1.5T/3T platforms.
China-based manufacturers expand access through lower-cost systems, domestic procurement and growing international distribution.
31 July 2026: FDA cleared Siemens MAGNETOM Flow.Elite, Flow.Neo, Flow.Rise and Flow.Pure, expanding the company's current Flow platform in the U.S. market.
23 June 2026: InHealth introduced the UK's first hybrid relocatable MAGNETOM Flow.Elite installation, demonstrating a flexible deployment model for helium-independent MRI capacity.
23 February 2026: FDA cleared updated MAGNETOM Flow.Ace and Flow.Plus configurations under 510(k) K260265.
19 February 2026: GE HealthCare announced FDA clearances for SIGNA Sprint with Freelium, SIGNA Bolt and the SIGNA One AI workflow ecosystem.
2 February 2026: Wipro GE HealthCare launched the Made-in-India SIGNA Prime Elite MRI system, emphasizing AI-powered reconstruction and lower helium consumption.
The global MRI system market is projected to grow from USD 6.06 billion in 2026 to USD 8.10 billion by 2034, at a 3.7% CAGR. Mature-market replacement, helium-independent 1.5T systems, AI productivity and Asia-Pacific infrastructure investment will be the main growth pillars.
| Forecast Variable | Current Direction | Expected Effect Through 2034 |
|---|---|---|
| Installed-base replacement | Mature regions have large existing MRI fleets. | Supports steady upgrades rather than explosive unit growth. |
| AI reconstruction | Faster acquisition and automation are moving into standard platforms. | Raises throughput and strengthens replacement economics. |
| Helium-independent magnets | Major vendors now offer sealed low-helium solutions. | Reduces siting and lifecycle barriers. |
| 3T / advanced imaging | Premium neuro, cardiac and oncology demand continues. | Supports higher system value. |
| Asia-Pacific expansion | Hospital and diagnostic-center capacity is rising rapidly. | Creates strongest net-new installation growth. |
The study is structured to support diagnostic-imaging strategy, capital-equipment procurement, product planning, market entry and competitive benchmarking.
Market sizing combines bottom-up supplier, product and pricing analysis with top-down demand validation. Bottom-up analysis evaluates product portfolios, installed systems or procedure volumes, pricing, replacement or replenishment cycles, end-user mix and distribution. Top-down validation uses disease burden, healthcare infrastructure, regulatory activity, treatment or diagnostic access and regional spending.
Primary research validates purchasing criteria, clinical workflow, product differentiation, adoption barriers and competitive positioning. Secondary research prioritizes regulators, public-health bodies, professional organizations, peer-reviewed evidence and official company product information. Forecasts are cross-checked against utilization, product lifecycle, pricing and regional infrastructure trends.
Forecasts incorporate MRI system revenue, replacement cycles, new installations, field-strength mix, hospital and diagnostic-center capital expenditure, average selling price, regional scanner density, AI-enabled upgrade demand and the migration toward sealed low-helium magnet platforms. Mature markets are modeled primarily through replacement and premiumization, while emerging markets receive stronger net-new installation assumptions.
The market was valued at USD 5.84 billion in 2025 and is estimated at USD 6.06 billion in 2026. It is projected to reach USD 8.10 billion by 2034, representing a 3.7% CAGR.
Superconducting MRI systems are the leading type and account for roughly 80% of the core market because they support mainstream 1.5T, 3T and ultra-high-field imaging.
North America is the largest regional market, supported by high scanner density, advanced healthcare spending and early adoption of premium and AI-enabled MRI systems.
1.5T remains the mainstream clinical field strength, while 3T is the premium growth tier and lower-field systems are re-emerging through improved AI reconstruction and easier siting.
Vendors are shifting toward sealed magnets with dramatically reduced helium requirements, improving sustainability and reducing siting and quench-infrastructure complexity.
The report profiles GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, United Imaging, Fujifilm/Hitachi, Neusoft, Anke, Alltech and Wandong Medical.
Deep-learning reconstruction and automated workflow can reduce acquisition time, standardize protocols and improve throughput, making software capability a major system-purchase criterion.
The public overview uses 2025 as the base year, 2026 as the estimated year and 2026–2034 as the forecast period.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
